Related Experiment Video
Updated: Oct 17, 2025

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.4K
Comparing different algorithms for the course of Alzheimer's disease using machine learning
1Department of Radiology, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Annals of Palliative Medicine
|October 11, 2021
Summary
The Random Forest (RF) classifier demonstrated superior performance in distinguishing Alzheimer's disease (AD) stages using brain MRI data. This machine learning approach aids in early AD diagnosis by accurately classifying cognitive normal, mild cognitive impairment (MCI), and AD groups.
Area of Science:
- Neuroimaging
- Machine Learning
- Neurology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder impacting memory, thinking, and language.
- Brain Magnetic Resonance Imaging (MRI) offers characteristic indexes valuable for AD assessment.
- Early and accurate diagnosis of AD and its precursor stages, like Mild Cognitive Impairment (MCI), is crucial for effective management.
Purpose of the Study:
- To evaluate the efficacy of machine learning algorithms in classifying and predicting the progression of Alzheimer's disease using MRI data.
- To identify the optimal machine learning model for auxiliary diagnosis of AD based on characteristic MRI indexes.
- To compare the performance of Random Forest (RF), Decision Tree (DT), and Support Vector Machine (SVM) algorithms in differentiating AD stages.
Main Methods:
- Utilized data from 560 subjects in the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.
- Classified subjects into four groups: Cognitive Normal (CN), Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI), and Alzheimer's Disease (AD).
- Applied RF, DT, and SVM algorithms to MRI characteristic indexes for classification and prediction, comparing accuracy, sensitivity, specificity, and AUC.
Main Results:
- The Random Forest (RF) classifier achieved the highest classification accuracy (73.8%) among the evaluated machine learning algorithms.
- RF demonstrated superior performance in predicting transitions between disease stages, particularly between Cognitive Normal (CN) and Alzheimer's Disease (AD) (AUC=0.92).
- Classification accuracy varied across disease stages, with CN-AD showing the highest accuracy, followed by EMCI-AD and CN-LMCI.
Conclusions:
- The Random Forest (RF) classifier is highly effective for classifying different stages of Alzheimer's disease, including early-stage detection.
- Specific MRI indexes, when utilized as features in the RF model, yield optimal prediction outcomes for AD progression.
- The RF classifier shows significant potential as an auxiliary tool to assist clinicians in the early diagnosis and classification of AD.
Related Concept Videos
Alzheimer's Disease: Treatment
294
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
294
Alzheimer's Disease: Overview
755
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
755

